Department of Anaesthesiology and Critical Care Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Department of Anaesthesiology and Critical Care Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Br J Anaesth. 2019 Apr;122(4):437-447. doi: 10.1016/j.bja.2019.01.014. Epub 2019 Feb 22.
A pulmonary hypertensive crisis (PHC) can be a life-threatening condition. We established a PHC model by exposing rats with monocrotaline (MCT)-induced pulmonary hypertension to acute hypoxia, and investigated the effects of vasopressin, phenylephrine, and norepinephrine on the PHC.
Four weeks after MCT 60 mg kg administration i.v., right ventricular systolic pressure (RVSP), systolic BP (SBP), mean BP (MBP), cardiac index (CI), and pulmonary vascular resistance index (PVRI) were measured. PHC defined as an RVSP exceeding or equal to SBP was induced by changing the fraction of inspiratory oxygen to 0.1. Rats were subsequently treated by vasopressin, phenylephrine, or norepinephrine, followed by assessment of systemic haemodynamics, isometric tension of femoral and pulmonary arteries, cardiac function, blood gas composition, and survival.
PHC was associated with increased RV dilatation and paradoxical septal motion. Vasopressin increased MBP [mean (standard error)] from 52.6 (3.8) to 125.0 (8.9) mm Hg and CI from 25.4 (2.3) to 40.6 (1.8) ml min 100 g while decreasing PVRI. Vasopressin also improved RV dilatation, oxygenation, and survival in PHC. In contrast, phenylephrine increased MBP from 54.8 (2.3) to 96.8 (3.2) mm Hg without improving cardiac pump function. Norepinephrine did not alter MBP. Vasopressin contracted femoral but not pulmonary arteries, whereas phenylephrine contracted both arterial beds. Hence, improvements with vasopressin in PHC might be associated with decreased PVRI and selective systemic vasoconstriction.
In this rat model of a PHC, vasopressin, but not phenylephrine or norepinephrine, resulted in better haemodynamic and vascular recovery.
肺动脉高压危象(PHC)可能是一种危及生命的情况。我们通过使患有单环酸(MCT)诱导的肺动脉高压的大鼠暴露于急性低氧中来建立 PHC 模型,并研究了血管加压素、苯肾上腺素和去甲肾上腺素对 PHC 的影响。
在静脉注射 MCT 60mg/kg 后 4 周,测量右心室收缩压(RVSP)、收缩压(SBP)、平均血压(MBP)、心指数(CI)和肺血管阻力指数(PVRI)。通过将吸气氧分数改为 0.1 来诱导 PHC,定义为 RVSP 超过或等于 SBP。随后用血管加压素、苯肾上腺素或去甲肾上腺素治疗大鼠,然后评估全身血液动力学、股动脉和肺动脉的等长张力、心功能、血气组成和存活率。
PHC 与 RV 扩张和反常隔运动有关。血管加压素使 MBP[平均值(标准误差)]从 52.6(3.8)增加到 125.0(8.9)mmHg,CI 从 25.4(2.3)增加到 40.6(1.8)ml/min/100g,同时降低 PVRI。血管加压素还改善了 PHC 中的 RV 扩张、氧合和存活率。相比之下,苯肾上腺素使 MBP 从 54.8(2.3)增加到 96.8(3.2)mmHg,但不改善心脏泵功能。去甲肾上腺素不改变 MBP。血管加压素收缩股动脉但不收缩肺血管,而苯肾上腺素收缩两个动脉床。因此,血管加压素在 PHC 中的改善可能与 PVRI 降低和选择性全身血管收缩有关。
在这种 PHC 大鼠模型中,血管加压素而非苯肾上腺素或去甲肾上腺素导致更好的血液动力学和血管恢复。